Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents

Recent improvements have been made in the treatment of hepatitis C virus (HCV) infection with the introduction of direct-acting antiviral agents (DAAs). However, despite successful viral clearance, many patients continue to have HCV-related disease progression. Therefore, new treatments must be deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kishta, Sara Sobhy, Kishta, Sobhy Ahmed, El-Shenawy, Reem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2017
Materias:
Opinion Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988296/
https://www.ncbi.nlm.nih.gov/pubmed/27583130
http://dx.doi.org/10.12688/f1000research.7970.3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988296/
https://www.ncbi.nlm.nih.gov/pubmed/27583130
http://dx.doi.org/10.12688/f1000research.7970.3

Ejemplares similares